ArticleAsian Pacific journal of cancer prevention : APJCP2024
Telomerase Gene Expression in Relation to Serum Protein and Hematological Parameters in Acute Myeloid Leukemia Patients.
Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveAcute myeloid leukemia (AML) is a hematological malignancy marked by the abnormal proliferation of myeloid precursor cells (blasts) in the bone marrow and peripheral blood, leading to disrupted blood cell production. The telomerase reverse transcriptase (hTERT), a key component of the telomerase enzyme, is often overexpressed in various cancers, including AML, contributing to cellular immortality. This study aimed to investigate the expression levels of the hTERT gene, serum protein concentrations, and hematological parameters in newly diagnosed AML patients, comparing these findings to AML patients in remission and healthy controls.
methodsBlood samples were collected from three groups: 10 newly diagnosed AML patients, 35 AML patients in remission, and 40 healthy controls. Hematological parameters, including white blood cell (WBC), red blood cell (RBC), platelet (PLT), and hemoglobin (Hb) levels, were measured. Serum hTERT protein concentrations were analyzed using enzyme-linked immunosorbent assay (ELISA), and hTERT gene expression was assessed through reverse transcription-quantitative PCR (RT-qPCR).
resultThe study demonstrated that newly diagnosed AML patients had significantly higher hTERT gene expression and serum protein levels compared to both remission patients and healthy individuals. Hematological analyses revealed elevated WBC counts alongside reduced RBC, PLT, and Hb levels in AML patients relative to controls.
conclusionIncreased hTERT expression and serum protein levels are valuable biomarkers for diagnosing and monitoring AML. These findings highlight the therapeutic potential of targeting hTERT and underscore the importance of conducting further studies on larger patient cohorts to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.